Ebronucimab clinical trials
Also written AK102.
How each study uses ebronucimab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the ebronucimab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
9 studies that test it; most in 2019 (2)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2019 | 2 |
| 2020 | 1 |
| 2021 | 2 |
| 2022 | 1 |
| 2024 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 9 · Other 0
Studies
Open first, then newest update. How each study uses ebronucimab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 9
- A Study Evaluating the Single Subcutaneous Injection of Ebronucimab in Chinese Healthy Male SubjectsNot yet recruitingPhase 1AkesoNCT06641388Written as Ebronucimab
- A Study Evaluating the Single Subcutaneous Injection of Ebronucimab in Healthy Male Chinese SubjectsCompletedPhase 1AkesoNCT07043283Written as Ebronucimab
- A Study to Evaluate the Efficacy and Safety of AK102 in Patients With HyperlipidemiaCompletedPhase 3AkesoNCT05255094Written as AK102
- A Study to Evaluate the Efficacy and Safety of AK102 Q6W in Patients With HyperlipidemiaCompletedPhase 3AkesoNCT05260411Written as AK102
- A Study to Evaluate the Long-term Efficacy and Safety of AK102 in Patients With HyperlipidemiaCompletedPhase 3AkesoNCT05255458Written as AK102
- A Study of PCSK9 Inhibitor AK102 in Healthy SubjectsCompletedPhase 1AkesoNCT04169386Written as AK102
- A Study of PCSK9 Inhibitor AK102 in Patients With HypercholesterolemiaCompletedPhase 2AkesoNCT04358432Written as AK102
- A Study to Evaluate the Safety and Efficacy of the PCSK9 Inhibitor AK102 in Patients With HoFHCompletedPhase 2AkesoNCT03933293Written as AK102
- A Study of PCSK9 Inhibitor AK102 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH)CompletedPhase 2AkesoNCT04173793Written as AK102
Codes
What other systems call ebronucimab · ClinicalTrials.gg INT016258
- UNII (FDA) CXX4Q31AAOEBRONUCIMABOne source FDA
- NCI Thesaurus C175774EbronucimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | CXX4Q31AAO | EBRONUCIMAB | One source FDA |
| NCI Thesaurus | C175774 | Ebronucimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.